Summary
This prediction ended on 01.11.18 with a price of €13.53. The price of Merus BV has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -16.67%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merus BV | - | - | - | - |
| iShares Core DAX® | 1.717% | 3.368% | 5.887% | 52.377% |
| iShares Nasdaq 100 | -4.565% | -4.238% | 21.386% | 72.449% |
| iShares Nikkei 225® | -7.120% | -11.869% | 42.357% | 57.579% |
| iShares S&P 500 | -0.894% | 1.687% | 19.495% | 62.154% |
Comments by stratec for this prediction
In the thread Merus BV diskutieren
Merus will yield meaningful clinical data in the near future.
A lucrative partnership was signed with Incyte last year for which they received $120 million upfront and a common share purchase of $80 million. Incyte in return received exclusive rights for up to 11 bispecific antibody research programs utilizing Merus' Biclonics technology, which included two preclinical immuno-oncology candidates.
The technology of Merus has the potential to be sufficiently differentiated from monoclonal antibodies due to improved tumor cell killing activity and lower toxicity.
(Laufzeit überschritten)